Daniela Bota
0000-0002-9680-9060
University of California Irvine
224 papers found
Refreshing results…
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data
Ctim-33. Phase Ii Trial of Vaccine Immunotherapy in Primary Glioblastoma: Adjunctive Autologous Dendritic Cells Pulsed With Lysate From Irradiated Self-Renewing Autologous Tumor Cells (Av-GBM-1)
Ddre-31. Mitochondrial Trafficking as a Target for GBM Therapy
Ddre-38. Magmas Inhibition in Medulloblastoma Cell Cultures and Patient-Derived Xenograft Models: Potential Therapeutic Implications
NCMP-13. Id8 Ovarian Cancer Mouse Model Mimics Neurological Sequelae of Ovarian Cancer in Women
Ctni-53. Radiation Treatment Volumes Before and After Braf/Mek Therapy in Newly Diagnosed Papillary Craniopharyngiomas: A Correlative Analysis of the Alliance A071601 Phase Ii Trial
Innv-29. Bilateral Parietal Lymphoma Lesions Responded Differently to Hd-MTX and Rituximab/Temozolomide Therapy
Ctni-08. Db102-01 Engage Study: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Clinical Trial of Db102 in Patients With Newly Diagnosed Glioblastoma (Gbm)
Innv-28. Potential Effective Consolidation Therapy With Single Agent Ibrutinib for a Case With Primary CNS Lymphoma After Initial Hd-MTX and Rituximab Induction Therapy
DDRE-50. INVESTIGATING THE ROLE OF LonP1 IN GLIOBLASTOMA TUMOR PROGRESSION
Immu-27. Long Term Stabilization of Recurrent High-Grade Glioma With Pd-1 Inhibitor Pembrolizumab in Two Cases
333 Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma
332 Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma
335 Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma
952 Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma
336 Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma
Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients
Characterization of neoepitope (neoE)-specific T cells from peripheral blood for adoptive neoTCR-T cell therapy for patients with breast cancer (bc) or ovarian cancer (oc).
Abstract 331: Characterization of neoepitope (neoE)-specific T cells from peripheral blood for adoptive neoTCR-T cell therapy for patients with breast cancer (bc) or ovarian cancer (oc)
Missing publications? Search for publications with a matching author name.